Literature DB >> 15354742

Immunohistochemical detection of P504S in primary and metastatic renal cell carcinomas.

Fan Lin1, Robert E Brown, Ting Shen, Ximing J Yang, Conrad Schuerch.   

Abstract

P504S/alpha-methylacryl CoA racemase has been shown to be a relatively sensitive and specific positive marker for prostatic adenocarcinoma. The potential utility of P504S in renal cell neoplasms has not been explored in a large series. We assessed the diagnostic value of P504S in 332 cases of nonprostatic neoplasms using the avidin-biotin-peroxidase complex technique, including 115 renal neoplasms, 28 metastatic renal cell carcinomas (RCCs), and 189 nonrenal neoplasms. The results demonstrated that a granular, cytoplasmic staining pattern for P504S was observed in 48 of 70 (68.6%) conventional (clear cell) RCCs, 15 of 15 (100%) papillary RCCs, 2 of 7 (29%) chromophobe RCCs, and 2 of 8 (25%) oncocytomas. Among the 70 cases of clear cell RCC, positivity of P504S was seen in 40%, 71%, 94%, and 75% of RCCs with Furhman nuclear grade I, II, III, and IV, respectively. Strong immunostaining was present in each case (86/86) in the proximal tubules adjacent to the renal neoplasm. Eighty-two percent of metastatic RCCs (23/28) were positive for P504S. However, only 24 of 189 (13%) nonrenal malignancies were positive. The 24 positive cases included 12 of 13 (92%) colorectal adenocarcinomas, 6 of 30 (20%) ductal carcinomas of the breast, and 4 of 23 (17%) adenocarcinomas of the lung. These findings suggest that P504S is a useful marker in diagnosing primary and metastatic RCCs, although it has little value in differentiating chromophobe RCC from oncocytoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354742     DOI: 10.1097/00129039-200406000-00010

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  7 in total

1.  Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma.

Authors:  Christian Eichelberg; Sarah Minner; Hendrik Isbarn; Eike Burandt; Luigi Terracciano; Holger Moch; Alexandra Kell; Roman Heuer; Felix K Chun; Guido Sauter; Margit Fisch; Pierre Tennstedt
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

2.  Typing of renal tumors by morphological and immunocytochemical evaluation of fine needle aspirates.

Authors:  Margareta Strojan Fležar; Helena Gutnik; Jera Jeruc; Irena Srebotnik Kirbiš
Journal:  Virchows Arch       Date:  2011-11-04       Impact factor: 4.064

3.  Molecular classification of renal tumors by gene expression profiling.

Authors:  Audrey N Schuetz; Qiqin Yin-Goen; Mahul B Amin; Carlos S Moreno; Cynthia Cohen; Christopher D Hornsby; Wen Li Yang; John A Petros; Muta M Issa; John G Pattaras; Kenneth Ogan; Fray F Marshall; Andrew N Young
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

4.  Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.

Authors:  Cord Langner; Gerhild Rupar; Sebastian Leibl; Georg Hutterer; Thomas Chromecki; Gerald Hoefler; Peter Rehak; Richard Zigeuner
Journal:  Virchows Arch       Date:  2005-11-29       Impact factor: 4.064

5.  Cytogenetic and immunohistochemical study of 42 pigmented microcystic chromophobe renal cell carcinoma (PMChRCC).

Authors:  Francisco Javier Queipo Gutiérrez; Ángel Panizo; Antonio Tienza; Irene Rodriguez; Jesús Javier Sola; Jordi Temprana-Salvador; Inés de Torres; Javier Pardo-Mindán
Journal:  Virchows Arch       Date:  2018-06-21       Impact factor: 4.064

6.  Vimentin 3, the new hope, differentiating RCC versus oncocytoma.

Authors:  Melanie von Brandenstein; Katharina Puetz; Monika Schlosser; Heike Löser; Joachim P Kallinowski; Daniel Gödde; Reinhard Buettner; Stefan Störkel; Jochen W U Fries
Journal:  Dis Markers       Date:  2015-04-07       Impact factor: 3.434

7.  Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy.

Authors:  Lisha Wang; Sean R Williamson; Mingsheng Wang; Darrell D Davidson; Shaobo Zhang; Lee Ann Baldridge; Xiang Du; Liang Cheng
Journal:  Mol Cancer       Date:  2014-02-26       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.